Veeva Systems Inc. (NYSE: VEEV) is a leading provider of cloud software specifically designed for the life sciences industry. The company focuses on customer relationship management (CRM), data analytics, and related solutions for pharmaceutical and biotech firms.

In its Fiscal 2026 first quarter earnings report for the quarter ending April 30, 2025, Veeva demonstrated significant growth, reporting total revenues of $759 million, an increase of 17% year-over-year from $650.3 million. Subscription services revenue reached $634.8 million, up 19% year-over-year from $534 million.

Operating income surged 51% to $233.7 million, from $155.2 million a year earlier. Veeva’s non-GAAP operating income also increased by 34% to $349.9 million compared to $260.9 million during the same quarter last year. The net income rose to $228.2 million, reflecting a 41% increase from $161.7 million in the previous year. Non-GAAP net income stood at $327.8 million, a 33% increase from $247.0 million.

The earnings per share figures mirrored this positive trend, with the fully diluted net income per share rising to $1.37 from $0.98, while non-GAAP diluted net income per share increased to $1.97 from $1.50.

Looking at guidance for the fiscal second quarter of 2026, Veeva projects total revenues to be between $766 million and $769 million, with non-GAAP operating income expected to be between $335 million and $337 million. The company also anticipates a non-GAAP diluted net income per share of approximately $1.89 to $1.90.

For the entire fiscal year ending January 31, 2026, updated guidance forecasts total revenues to lie between $3.09 billion and $3.1 billion, with non-GAAP operating income projected to be around $1.36 billion. Non-GAAP fully diluted net income per share is expected to be approximately $7.63.

The company achieved a significant milestone of surpassing its 2025 revenue run rate goal of $3 billion. Additionally, Veeva is advancing towards its 2030 goal of doubling revenue, highlighting the ongoing strong demand for its solutions in the life sciences sector.